novo glp-1 drug Nordisk plans to slash prices More than a third of

Understanding their mechanisms, benefits, and associated risks will remain essential as their role in clinical medicine continues to expand

In our experience, transitioning directly to subcutaneous semaglutide 1 mg once weekly from another GLP-1 receptor agonist can be associated with nausea or GI disturbance

Expert Opinion GLP-1 receptor agonists, along with dual and triple agonists, have transformed the landscape of adolescent obesity treatment, offering an effective alternative to lifestyle interventions that often fail to produce long-term results

Unlike semaglutide and tirzepatide, which can be compounded because they have FDA-approved reference products, retatrutide has no approved form to compound from

Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors